FDA Webview
X
about-us-banner

Pay Per View

Home / Pay Per View

Panel Backs Mesoblast BLA for Graft Versus Host Disease

[ Price : $8.95]

FDAs Oncologic Drugs Advisory Committee votes nine to one in favor of approving a Mesoblast BLA for Ryoncil (remestemcell-L) as a ...

Bone Growth Stimulator Proposed Reclassification

[ Price : $8.95]

Federal Register notice: FDA proposes to reclassify non-invasive bone growth stimulators from postamendments Class 3 devices into ...

Untitled Letter Objects to Web Claims by Cell Therapy Firm

[ Price : $8.95]

CBERs Office of Compliance and Biologics Quality sends East West Health Solutions (Lake City, UT) an untitled letter based on a re...

De Novo Authorization for Glycemic Controller

[ Price : $8.95]

FDA authorizes the de novo marketing of Tandem Diabetes Cares Control-IQ Technology, an interoperable automated glycemic controlle...

Irradiation Regulation Repeal to Help OTC Drugs

[ Price : $8.95]

Federal Register notice: FDA issues a final rule to repeal a regulation that required an FDA-approved NDA or ANDA for any drug pro...

Boston Scientific Disposable Duodenoscope Cleared

[ Price : $8.95]

FDA clears a Boston Scientific 510(k) for its Exalt Model D Single-Use Duodenoscope.

Draft Guide on Drug Development Tools Qualification

[ Price : $8.95]

FDA releases a draft guidance on Qualification Process for Drug Development Tools Guidance for Industry and FDA Staff.

Amarin Gains Expanded Use for Vascepa

[ Price : $8.95]

FDA approves the expanded use of Amarins Vascepas (icosapent ethyl) to reduce the risk of cardiovascular events as an adjunct to s...

Final Rule on Device e-Submissions

[ Price : $8.95]

Federal Register notice: FDA issues a final rule amending requirements for medical device premarket submissions to require a singl...

Draft Guide on Pediatric Oncology Drugs

[ Price : $8.95]

Federal Register: FDA makes available a draft guidance entitled FDARA Implementation Guidance for Pediatric Studies of Molecularly...